Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial.
AffiliationGynaecology Oncology Research Group, School of Cancer and Enabling Sciences, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractBody mass index (BMI) is a major risk factor for endometrial cancer incidence but its impact on post-treatment survival is unclear. We investigated the relationships of BMI (categorised using the WHO definitions) with clinico-pathological characteristics and outcome in women treated within the MRC ASTEC randomised trial, which provides data from patients who received standardised allocated treatments and therefore reduces biases. The impact of BMI on both recurrence-free survival (RFS) and overall survival (OS) was analysed using the Cox regression models. An apriori framework of evaluating potential biases was explored. From 1408 participants, there were 1070 women with determinable BMI (median=29.1 kg/m(2)). Histological types were endometrioid (type 1) in 893 and non-endometrioid (type 2) in 146 women; the proportion of the latter decreasing with increasing BMI (8% versus 19% for obese III WHO category versus normal weight, p(trend)=0.003). For type 1 carcinomas, increasing BMI was associated with less aggressive histopathological features (depth of invasion, p=0.006; tumour grade, p=0.015). With a median follow-up of 34.3 months, there was no influence of BMI on RFS - adjusted HRs per 5 kg/m(2) were 0.98 (95% CI 0.86, 1.13) and 0.95 (0.74, 1.24), for type 1 and 2 carcinomas; and no influence on OS - adjusted HRs per 5 kg/m(2) were 0.96 (0.81, 1.14) and 0.92 (0.70, 1.23), respectively. These findings demonstrate an important principle: that an established link between an exposure (here, obesity) and increased incident cancer risk, does not necessarily translate into an inferior outcome following treatment for that cancer.
CitationBody mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. 2012, 48 (6):853-64 Eur J Cancer
JournalEuropean Journal of Cancer
- Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
- Authors: de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, PORTEC study group.
- Issue date: 2018 Mar
- [Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
- Authors: Tian WY, Wang YM, Yan Y, Gao JP, Sun DD, Jiang S, Sheng Y, Teng F, Xue FX
- Issue date: 2016 Nov 25
- [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
- Authors: Wang Y, Yu M, Yang JX, Cao DY, Zhang Y, Shen K, You Y
- Issue date: 2018 Dec 25
- L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
- Authors: Pasanen A, Tuomi T, Isola J, Staff S, Bützow R, Loukovaara M
- Issue date: 2016 Oct
- Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center.
- Authors: Tai YJ, Hsu HC, Chiang YC, Chen YL, Chen CA, Cheng WF
- Issue date: 2019 Jul 18